For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Net revenues | - | 0 | - | - |
| Research and development expense | 1,633,476 | 1,039,713 | 1,958,602 | 1,053,328.5* |
| General and administrative expenses | 2,447,188 | 1,159,936 | 1,517,415 | 1,494,965.5* |
| Total operating expenses | 4,080,664 | 2,199,649 | 3,476,017 | 2,548,294 |
| Loss from operations | -4,080,664 | -2,199,649 | -3,476,017 | -2,548,294* |
| Unrealized loss on crypto assets | 25,305 | - | - | - |
| Dividend and interest income | 168 | 173 | 181 | 6,929.75* |
| Change in fair value of investment in joint ventures | - | 0 | - | -145.25* |
| Total other income (expenses), net | -25,137 | 173 | 181 | 6,784.5* |
| Net loss | -4,105,801 | -2,199,476 | -3,475,836 | -2,541,509.5* |
| Foreign currency translation adjustment | -1,016 | 3,478 | -497 | -24,383* |
| Total comprehensive loss | -4,106,817 | -2,195,998 | -3,476,333 | -2,565,892.5 |
| Basic EPS | -0.3 | -0.17 | -0.27 | -0.48 |
| Diluted EPS | -0.3 | -0.17 | -0.27 | -0.48 |
| Basic Average Shares | 13,787,159 | 13,180,243 | 12,727,581 | 5,345,348 |
| Diluted Average Shares | 13,787,159 | 13,180,243 | 12,727,581 | 5,345,348 |
Hoth Therapeutics, Inc. (HOTH)
Hoth Therapeutics, Inc. (HOTH)